How Do Outcomes for Relapsed/Refractory Follicular Lymphoma Vary?
How do relapsed/refractory follicular lymphoma outcomes differ? Expert Dr. Brad Kahl from Washington University School of Medicine discusses response of initial treatment versus relapsed disease in the past and the results with newer treatments for relapsed disease.
Download Resource Guide | Descargar Guía
See More from START HERE Follicular Lymphoma
Related Resources:
|
|
Defining Survivorship for Relapsed/Refractory Follicular Lymphoma |
Transcript:
Lisa Hatfield:
Another question, Dr. Kahl. How do outcomes differ for patients with relapsed/refractory disease compared to those who respond well to initial treatment?
Dr. Brad Kahl:
So that’s a really good question. And when we have a patient going through frontline treatment, we’re all really crossing our fingers that that first remission is incredibly durable. Because when the disease relapses, the remissions do tend to get shorter and shorter and shorter, which is frustrating for everybody.And so we love it when we get a nice long first remission. And in the older days when all we had to offer was chemotherapy and some different immunochemotherapy regimens, the remissions in second line and third line might be two years or one year.
It can get frustrating as you go through treatment after treatment after treatment. It’s hard on patients. The side effects start to accumulate. And that’s one of the reasons we’re so excited about all these new agents that we have for relapsed disease with the bispecifics and the CAR T products and the small molecule inhibitors like tazemetostat (Tazverik) and zanubrutinib (Brukinsa). Because it appears as though these remissions for relapsed disease might be getting longer than what we have seen historically. So there’s no question that dealing with relapsed follicular lymphoma is more difficult than dealing with frontline follicular lymphoma. But we’re optimistic that these newer treatments we have are improving outcomes for patients with relapsed disease.
